Results 171 to 180 of about 26,835 (181)

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Lancet Oncology, The, 2014
Grant A Mcarthur, Paul B Chapman, Caroline Robert   +2 more
exaly  

HCL — vemurafenib plus rituximab holds promise

Nature Reviews Clinical Oncology, 2021
exaly  

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

Lancet Oncology, The, 2014
James Larkin, Michele Del Vecchio, Paolo A Ascierto   +2 more
exaly  

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Lancet Oncology, The, 2018
Michele Maio, Karl Lewis, Igor N Bondarenko   +2 more
exaly  

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Lancet Oncology, The, 2016
Marcia S Brose, Maria E Cabanillas, Lori J Wirth   +2 more
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
exaly  

Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin

Biomaterials, 2018
Wei-Ping Ding, Fenfen Li, Peng-Fei Wei
exaly  

Vemurafenib

Nature Reviews Drug Discovery, 2011
exaly  

Vemurafenib

Reactions Weekly, 2020
openaire   +1 more source

Intermittent vemurafenib prevents resistance in melanoma

Nature Reviews Clinical Oncology, 2013
exaly